001018548 001__ 1018548
001018548 005__ 20231213115653.0
001018548 0247_ $$2doi$$a10.1007/s11060-023-04444-x
001018548 0247_ $$2ISSN$$a0167-594X
001018548 0247_ $$2ISSN$$a1573-7373
001018548 0247_ $$2datacite_doi$$a10.34734/FZJ-2023-04876
001018548 0247_ $$2pmid$$a37728779
001018548 0247_ $$2WOS$$aWOS:001068390300001
001018548 037__ $$aFZJ-2023-04876
001018548 082__ $$a610
001018548 1001_ $$0P:(DE-HGF)0$$aZeyen, Thomas$$b0
001018548 245__ $$aUndetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses
001018548 260__ $$aDordrecht [u.a.]$$bSpringer Science + Business Media B.V$$c2023
001018548 3367_ $$2DRIVER$$aarticle
001018548 3367_ $$2DataCite$$aOutput Types/Journal article
001018548 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1701182095_23345
001018548 3367_ $$2BibTeX$$aARTICLE
001018548 3367_ $$2ORCID$$aJOURNAL_ARTICLE
001018548 3367_ $$00$$2EndNote$$aJournal Article
001018548 500__ $$aErratum in Correction to: Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses. Zeyen T, Paech D, Weller J, Schäfer N, Tzaridis T, Duffy C, Nitsch L, Schneider M, Potthoff AL, Steinbach JP, Hau P, Schlegel U, Seidel C, Krex D, Grauer O, Goldbrunner R, Zeiner PS, Tabatabai G, Galldiks N, Stummer W, Hattingen E, Glas M, Radbruch A, Herrlinger U, Schaub C. J Neurooncol. 2023 Nov 3. doi: 10.1007/s11060-023-04488-z. 
001018548 520__ $$aPurpose: In the randomized CeTeG/NOA-09 trial, lomustine/temozolomide (CCNU/TMZ) was superior to TMZ therapy regarding overall survival (OS) in MGMT promotor-methylated glioblastoma. Progression-free survival (PFS) and pseudoprogression rates (about 10%) were similar in both arms. Further evaluating this discrepancy, we analyzed patterns of postprogression survival (PPS) and MRI features at first progression according to modified RANO criteria (mRANO).Methods: We classified the patients of the CeTeG/NOA-09 trial according to long vs. short PPS employing a cut-off of 18 months and compared baseline characteristics and survival times. In patients with available MRIs and confirmed progression, the increase in T1-enhancing, FLAIR hyperintense lesion volume and the change in ADC mean value of contrast-enhancing tumor upon progression were determined.Results: Patients with long PPS in the CCNU/TMZ arm had a particularly short PFS (5.6 months). PFS in this subgroup was shorter than in the long PPS subgroup of the TMZ arm (11.1 months, p = 0.01). At mRANO-defined progression, patients of the CCNU/TMZ long PPS subgroup had a significantly higher increase of mean ADC values (p = 0.015) and a tendency to a stronger volumetric increase in T1-enhancement (p = 0.22) as compared to long PPS patients of the TMZ arm.Conclusion: The combination of survival and MRI analyses identified a subgroup of CCNU/TMZ-treated patients with features that sets them apart from other patients in the trial: short first PFS despite long PPS and significant increase in mean ADC values upon mRANO-defined progression. The observed pattern is compatible with the features commonly observed in pseudoprogression suggesting mRANO-undetected pseudoprogressions in the CCNU/TMZ arm of CeTeG/NOA-09.Keywords: Glioblastoma; MGMT promotor methylation; MRI; Progression; Pseudoprogression.
001018548 536__ $$0G:(DE-HGF)POF4-5252$$a5252 - Brain Dysfunction and Plasticity (POF4-525)$$cPOF4-525$$fPOF IV$$x0
001018548 536__ $$0G:(GEPRIS)491111487$$aDFG project 491111487 - Open-Access-Publikationskosten / 2022 - 2024 / Forschungszentrum Jülich (OAPKFZJ) (491111487)$$c491111487$$x1
001018548 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
001018548 7001_ $$0P:(DE-HGF)0$$aPaech, Daniel$$b1
001018548 7001_ $$0P:(DE-HGF)0$$aWeller, Johannes$$b2
001018548 7001_ $$0P:(DE-HGF)0$$aSchäfer, Niklas$$b3
001018548 7001_ $$0P:(DE-HGF)0$$aTzaridis, Theophilos$$b4
001018548 7001_ $$0P:(DE-HGF)0$$aDuffy, Cathrina$$b5
001018548 7001_ $$0P:(DE-HGF)0$$aNitsch, Louisa$$b6
001018548 7001_ $$0P:(DE-HGF)0$$aSchneider, Matthias$$b7
001018548 7001_ $$0P:(DE-HGF)0$$aPotthoff, Anna-Laura$$b8
001018548 7001_ $$0P:(DE-HGF)0$$aSteinbach, Joachim Peter$$b9
001018548 7001_ $$0P:(DE-HGF)0$$aHau, Peter$$b10
001018548 7001_ $$0P:(DE-HGF)0$$aSchlegel, Uwe$$b11
001018548 7001_ $$0P:(DE-HGF)0$$aSeidel, Clemens$$b12
001018548 7001_ $$0P:(DE-HGF)0$$aKrex, Dietmar$$b13
001018548 7001_ $$0P:(DE-HGF)0$$aGrauer, Oliver$$b14
001018548 7001_ $$0P:(DE-HGF)0$$aGoldbrunner, Roland$$b15
001018548 7001_ $$0P:(DE-HGF)0$$aZeiner, Pia Susan$$b16
001018548 7001_ $$0P:(DE-HGF)0$$aTabatabai, Ghazaleh$$b17
001018548 7001_ $$0P:(DE-Juel1)143792$$aGalldiks, Norbert$$b18$$ufzj
001018548 7001_ $$0P:(DE-HGF)0$$aStummer, Walter$$b19
001018548 7001_ $$0P:(DE-HGF)0$$aHattingen, Elke$$b20
001018548 7001_ $$0P:(DE-HGF)0$$aGlas, Martin$$b21
001018548 7001_ $$0P:(DE-HGF)0$$aRadbruch, Alexander$$b22
001018548 7001_ $$0P:(DE-HGF)0$$aHerrlinger, Ulrich$$b23
001018548 7001_ $$00000-0002-5257-4183$$aSchaub, Christina$$b24$$eCorresponding author
001018548 773__ $$0PERI:(DE-600)2007293-4$$a10.1007/s11060-023-04444-x$$gVol. 164, no. 3, p. 607 - 616$$n3$$p607 - 616$$tJournal of neuro-oncology$$v164$$x0167-594X$$y2023
001018548 8564_ $$uhttps://juser.fz-juelich.de/record/1018548/files/PDF.pdf$$yOpenAccess
001018548 8564_ $$uhttps://juser.fz-juelich.de/record/1018548/files/PDF.gif?subformat=icon$$xicon$$yOpenAccess
001018548 8564_ $$uhttps://juser.fz-juelich.de/record/1018548/files/PDF.jpg?subformat=icon-1440$$xicon-1440$$yOpenAccess
001018548 8564_ $$uhttps://juser.fz-juelich.de/record/1018548/files/PDF.jpg?subformat=icon-180$$xicon-180$$yOpenAccess
001018548 8564_ $$uhttps://juser.fz-juelich.de/record/1018548/files/PDF.jpg?subformat=icon-640$$xicon-640$$yOpenAccess
001018548 909CO $$ooai:juser.fz-juelich.de:1018548$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
001018548 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)143792$$aForschungszentrum Jülich$$b18$$kFZJ
001018548 9101_ $$0I:(DE-HGF)0$$60000-0002-5257-4183$$a UK Bonn$$b24
001018548 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5252$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
001018548 9141_ $$y2023
001018548 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-20
001018548 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-20
001018548 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
001018548 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NEURO-ONCOL : 2022$$d2023-08-20
001018548 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-20
001018548 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2023-08-20$$wger
001018548 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-20
001018548 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-08-20
001018548 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
001018548 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-20
001018548 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-20
001018548 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-08-20$$wger
001018548 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-20
001018548 920__ $$lyes
001018548 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
001018548 980__ $$ajournal
001018548 980__ $$aVDB
001018548 980__ $$aUNRESTRICTED
001018548 980__ $$aI:(DE-Juel1)INM-3-20090406
001018548 9801_ $$aFullTexts